Abstract

BackgroundThe activation of T cells and imbalanced redox metabolism enhances the development of graft-versus-host disease (GVHD). Human placenta-derived mesenchymal stromal cells (hPMSCs) can improve GVHD through regulating T cell responses. However, whether hPMSCs balance the redox metabolism of CD4+IL-10+ T cells and liver tissue and alleviate GVHD remains unclear. This study aimed to investigate the effect of hPMSC-mediated treatment of GVHD associated with CD4+IL-10+ T cell generation via control of redox metabolism and PD-1 expression and whether the Nrf2 and NF-κB signaling pathways were both involved in the process.MethodsA GVHD mouse model was induced using 6–8-week-old C57BL/6 and Balb/c mice, which were treated with hPMSCs. In order to observe whether hPMSCs affect the generation of CD4+IL-10+ T cells via control of redox metabolism and PD-1 expression, a CD4+IL-10+ T cell culture system was induced using human naive CD4+ T cells. The percentage of CD4+IL-10+ T cells and their PD-1 expression levels were determined in vivo and in vitro using flow cytometry, and Nrf2, HO-1, NQO1, GCLC, GCLM, and NF-κB levels were determined by western blotting, qRT-PCR, and immunofluorescence, respectively. Hematoxylin-eosin, Masson’s trichrome, and periodic acid-Schiff staining methods were employed to analyze the changes in hepatic tissue.ResultsA decreased activity of superoxide dismutase (SOD) and a proportion of CD4+IL-10+ T cells with increased PD-1 expression were observed in GVHD patients and the mouse model. Treatment with hPMSCs increased SOD activity and GCL and GSH levels in the GVHD mouse model. The percentage of CD4+IL-10+ T cells with decreased PD-1 expression, as well as Nrf2, HO-1, NQO1, GCLC, and GCLM levels, both in the GVHD mouse model and in the process of CD4+IL-10+ T cell generation, were also increased, but NF-κB phosphorylation and nuclear translocation were inhibited after treatment with hPMSCs, which was accompanied by improvement of hepatic histopathological changes.ConclusionsThe findings suggested that hPMSC-mediated redox metabolism balance and decreased PD-1 expression in CD4+IL-10+ T cells were achieved by controlling the crosstalk between Nrf2 and NF-κB, which further provided evidence for the application of hPMSC-mediated treatment of GVHD.

Highlights

  • The activation of T cells and imbalanced redox metabolism enhances the development of graftversus-host disease (GVHD)

  • The percentage of CD4+IL-10+ T cells with decreased Programmed death-1 (PD-1) expression, as well as Nuclear factor-E2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), NQO1, glutamatecysteine ligase catalytic subunit (GCLC), and Glutamate-cysteine ligase regulatory subunit (GCLM) levels, both in the GVHD mouse model and in the process of CD4+IL-10+ T cell generation, were increased, but Nuclear factor kappa-B (NF-κB) phosphorylation and nuclear translocation were inhibited after treatment with Human placenta-derived mesenchymal stromal cells (hPMSCs), which was accompanied by improvement of hepatic histopathological changes

  • The findings suggested that hPMSC-mediated redox metabolism balance and decreased PD-1 expression in CD4+IL-10+ T cells were achieved by controlling the crosstalk between Nrf2 and NF-κB, which further provided evidence for the application of hPMSC-mediated treatment of GVHD

Read more

Summary

Introduction

The activation of T cells and imbalanced redox metabolism enhances the development of graftversus-host disease (GVHD). Human placenta-derived mesenchymal stromal cells (hPMSCs) can improve GVHD through regulating T cell responses. Whether hPMSCs balance the redox metabolism of CD4+IL-10+ T cells and liver tissue and alleviate GVHD remains unclear. The tissue damage caused by donor T cell activation, imbalanced proportion of T cell subsets, and oxidative stress after allogeneic hematopoietic stem cell transplantation (allo-HSCT) contributes to the development of graft-versus-host disease (GVHD), which is the main obstacle to the success of allo-HSCT treatment. It was reported that human placenta-derived mesenchymal stromal cells (hPMSCs) could improve GVHD by increasing the proportion of Th2 and CD4+CD25+FoxP3+ T cells via PD-L1 expressed on the hPMSC surface and by subsequently alleviating liver damage [1, 2]. Our previous results showed that hPMSCs could alleviate GVHD symptoms by maintaining the balance of CD4+IL-10+ T cells and Th17 subsets [6]; the specific mechanism by which hPMSCs regulate the generation of CD4+IL-10+ T cells remains unclear

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call